Investment Management Associates Inc. ADV Trims Position in Solventum Co. (NYSE:SOLV)

Investment Management Associates Inc. ADV trimmed its position in shares of Solventum Co. (NYSE:SOLV) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114,123 shares of the company’s stock after selling 775 shares during the period. Solventum accounts for 3.3% of Investment Management Associates Inc. ADV’s portfolio, making the stock its 14th largest holding. Investment Management Associates Inc. ADV’s holdings in Solventum were worth $7,539,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Trian Fund Management L.P. lifted its stake in Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after purchasing an additional 1,765,676 shares in the last quarter. State Street Corp increased its holdings in shares of Solventum by 3.1% in the third quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Solventum by 4.0% in the third quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock worth $232,608,000 after buying an additional 128,317 shares in the last quarter. Hotchkis & Wiley Capital Management LLC bought a new position in Solventum during the third quarter valued at approximately $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Solventum by 0.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock valued at $73,469,000 after buying an additional 3,745 shares in the last quarter.

Solventum Stock Up 0.6 %

Shares of SOLV opened at $74.44 on Friday. The firm has a fifty day moving average price of $71.07 and a 200-day moving average price of $68.95. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Piper Sandler increased their target price on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research report on Friday, November 8th. Morgan Stanley boosted their target price on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Mizuho assumed coverage on shares of Solventum in a report on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target for the company. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.